6FFG image
Entry Detail
PDB ID:
6FFG
Keywords:
TRANSCRIPTION
Title:
Human BRD2 C-terminal bromodomain with (S)-1-(2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-3,4-dihydroquinoxalin-1(2H)-yl)ethanone
Biological Source:
Source Organism:
Homo sapiens
Host Organism:
Escherichia coli
PDB Version:
Deposition Date:
2018-01-07
Release Date:
2019-01-30
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.59 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 2
6FFG validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:Bromodomain-containing protein 2
Chain IDs:A
Chain Length:115
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:P25440 Pfam ID:PF00439
Ligand Molecules
D7B
EDO
MES
PEG
Primary Citation
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
J.Med.Chem. 61 4317 4334 (2018)
PMID: 29656650 DOI: 10.1021/acs.jmedchem.7b01666

Abstact

The bromodomain and extra-terminal domain (BET) family of proteins bind acetylated lysine residues on histone proteins. The four BET bromodomains-BRD2, BRD3, BRD4, and BRDT-each contain two bromodomain modules. BET bromodomain inhibition is a potential therapy for various cancers and immunoinflammatory diseases, but few reported inhibitors show selectivity within the BET family. Inhibitors with selectivity for the first or second bromodomain are desired to aid investigation of the biological function of these domains. Focused library screening identified a series of tetrahydroquinoxalines with selectivity for the second bromodomains of the BET family (BD2). Structure-guided optimization of the template improved potency, selectivity, and physicochemical properties, culminating in potent BET inhibitors with BD2 selectivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
6FFD
6FFE
6FFF